EPS for Nuvectra Corporation (NVTR) Expected At $-1.03 on May, 8

April 16, 2018 - By Patrick Harkless

Nuvectra Corporation (NASDAQ:NVTR) Corporate Logo

On May, 8 WallStreet anticipated Nuvectra Corporation (NASDAQ:NVTR)’s earnings release, as reported by RTT. Analysts expect change of 18.90 % or $0.24 from previous year’s $-1.27 EPS compared to current’s $-1.03 EPS. Analysts at Wall Street see Nuvectra Corporation’s 28.75 % negative EPS growth compared to $-0.80 EPS for last quarter. On during the last trading session the stock increased $0.37 or 2.76%, reaching $13.76.Nuvectra Corporation has volume of 82,036 shares. Since April 17, 2017 NVTR has risen 92.78% and is uptrending. NVTR outperformed the S&P500 by 81.23%.

Nuvectra Corporation, a neuromodulation medical device company, develops and commercializes its neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets in Europe.The firm is worth $194.66 million. The firm offers Algovita spinal cord stimulation system that is used for the treatment of chronic pain of the trunk and limbs.Last it reported negative earnings. It also provides neural interface systems, including microelectrode arrays, probes, and electrode instrumentation and accessories; and develops Virtis, a sacral nerve stimulation system for the treatment of chronic urinary retention and the symptoms of overactive bladder.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.